These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7905836)

  • 1. PET- and MRI-based assessment of glucose utilization, dopamine receptor binding, and hemodynamic changes after lesions to the caudate-putamen in primates.
    Brownell AL; Hantraye P; Wullner U; Hamberg L; Shoup T; Elmaleh DR; Frim DM; Madras BK; Brownell GL; Rosen BR
    Exp Neurol; 1994 Jan; 125(1):41-51. PubMed ID: 7905836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-[18F]fluoro-L-dopa uptake and [76Br]bromolisuride binding in the excitotoxically lesioned caudate-putamen of nonhuman primates studied using positron emission tomography.
    Hantraye P; Loc'H C; Maziere B; Khalili-Varasteh M; Crouzel C; Fournier D; Yorke JC; Stulzaft O; Riche D; Isacson O
    Exp Neurol; 1992 Feb; 115(2):218-27. PubMed ID: 1531196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428.
    Wong DF; Yung B; Dannals RF; Shaya EK; Ravert HT; Chen CA; Chan B; Folio T; Scheffel U; Ricaurte GA
    Synapse; 1993 Oct; 15(2):130-42. PubMed ID: 8259524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease.
    Burns LH; Pakzaban P; Deacon TW; Brownell AL; Tatter SB; Jenkins BG; Isacson O
    Neuroscience; 1995 Feb; 64(4):1007-17. PubMed ID: 7753372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D1 and D2 dopamine receptors in caudate-putamen of nonhuman primates (Macaca fascicularis).
    Madras BK; Fahey MA; Canfield DR; Spealman RD
    J Neurochem; 1988 Sep; 51(3):934-43. PubMed ID: 2970527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon.
    Hantraye P; Riche D; Maziere M; Isacson O
    Exp Neurol; 1990 May; 108(2):91-104. PubMed ID: 2139853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A primate model of Huntington's disease: functional neural transplantation and CT-guided stereotactic procedures.
    Schumacher JM; Hantraye P; Brownell AL; Riche D; Madras BK; Davenport PD; Maziere M; Elmaleh DR; Brownell GL; Isacson O
    Cell Transplant; 1992; 1(4):313-22. PubMed ID: 1344304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative autoradiography of dopamine D2 sites in rat caudate-putamen: localization to intrinsic neurons and not to neocortical afferents.
    Joyce JN; Marshall JF
    Neuroscience; 1987 Mar; 20(3):773-95. PubMed ID: 2955247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unchanged striatal dopamine transporter availability in narcolepsy: a PET study with [11C]-CFT.
    Rinne JO; Hublin C; Någren K; Helenius H; Partinen M
    Acta Neurol Scand; 2004 Jan; 109(1):52-5. PubMed ID: 14653850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease.
    Roitberg BZ; Emborg ME; Sramek JG; Palfi S; Kordower JH
    Neurosurgery; 2002 Jan; 50(1):137-45; discussion 145-6. PubMed ID: 11844244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective up-regulation of D-1 dopamine receptors following chronic administration of SCH 39166 in primates.
    Duffy RA; Kaminska G; Chipkin RE; McQuade RD
    Pharmacol Biochem Behav; 1992 Jan; 41(1):235-8. PubMed ID: 1531704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey.
    Melega WP; Lacan G; Desalles AA; Phelps ME
    Synapse; 2000 Mar; 35(4):243-9. PubMed ID: 10657033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization.
    Ferrante RJ; Kowall NW; Cipolloni PB; Storey E; Beal MF
    Exp Neurol; 1993 Jan; 119(1):46-71. PubMed ID: 8432351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease.
    Araujo DM; Cherry SR; Tatsukawa KJ; Toyokuni T; Kornblum HI
    Exp Neurol; 2000 Dec; 166(2):287-97. PubMed ID: 11085894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of repeated injections of cocaine on catecholamine receptor binding sites, dopamine transporter binding sites and behavior in rhesus monkey.
    Farfel GM; Kleven MS; Woolverton WL; Seiden LS; Perry BD
    Brain Res; 1992 Apr; 578(1-2):235-43. PubMed ID: 1380862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT.
    Wüllner U; Pakzaban P; Brownell AL; Hantraye P; Burns L; Shoup T; Elmaleh D; Petto AJ; Spealman RD; Brownell GL
    Exp Neurol; 1994 Apr; 126(2):305-9. PubMed ID: 7925829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cocaine congeners as PET imaging probes for dopamine terminals.
    Brownell AL; Elmaleh DR; Meltzer PC; Shoup TM; Brownell GL; Fischman AJ; Madras BK
    J Nucl Med; 1996 Jul; 37(7):1186-92. PubMed ID: 8965196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.